Beatson Institute for Cancer Research

Beatson Institute for Cancer Research

Item
http://www.wikidata.org/entity/Q25188472
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)TroVax Renal Immunotherapy Survival TrialGemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerDose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With RuxolitinibCombination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell TumorsChemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric CancerCapecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal CancerGoserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast CancerA Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsCapecitabine or Observation After Surgery in Treating Patients With Biliary Tract CancerMale Breast Cancer: Understanding the Biology for Improved Patient CareMK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by SurgeryStudy of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast CancerA Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerBortezomib in Treating Patients With Malignant Pleural MesotheliomaCisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal CancerA Study To Establish the Prevalence of Mutations in Patients With CML and Ph+ ALL Currently Being Treated With TKI Therapy in the UKAcridine Carboxamide in Treating Patients With Recurrent Glioblastoma MultiformeHigh-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III MelanomaEpirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast CancerPNU 166148 in Treating Patients With Metastatic Solid TumorsMEN-10755 in Treating Adults With Recurrent or Refractory Solid TumorsDerazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic CholangiocarcinomaSafety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaCheckpOiNt Blockade For Inhibition of Relapsed MesotheliomaA Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursA Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast CancerA Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 DLUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based ChemotherapyA Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast CancerA Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial CancerA Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate CancerA Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic PainDonor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological CancersAzacitidine in Treating Patients With Chronic Myelomonocytic LeukemiaStudy of BGB-A317 in Patients With Previously Treated Unresectable HCCCANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell CarcinomaA Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
P6153
Q37373039-8B155230-933B-499E-93D5-091AC2F68382Q37373112-B7D858ED-3D90-45C7-89A7-7D21EF874C9AQ37383522-5FAB39A5-E38F-4306-97DA-ACBC5965B424Q37838436-1F1B2CCA-3405-422B-89DB-DA36E0827FA2Q38642375-6A582252-F05D-4747-8779-DC1A7384A2ECQ38802449-ADEB8F54-F854-4B94-87F8-606722A44BBCQ39422076-597D8EFD-7D70-43F7-A938-8FC6E2DD4BCAQ39631725-8CEE5AE2-565B-4497-B7F0-7D84F547A275Q42316501-F30C63BD-B902-4B5D-B124-922A9517E188Q42360952-3BD626F0-43CF-458B-81FD-C04E2E04688CQ42360952-C7FFB909-9B54-4F52-9EA9-7B9930D93FECQ42360952-D4251A38-9094-4C0D-930A-44389C4DA0CAQ42715847-7DB6F9D2-6B23-445C-9547-8E78A2E147A1Q42767386-7A08B0A1-AAFA-4F12-A50B-BC0F83F02FD1Q42772046-3AD5739F-8174-4DF9-A9AB-545213DC8FCCQ42876198-EB660438-0822-49B8-8C8A-ADFCFCD7CC9CQ42884532-33f31557-449c-e27c-3195-0b5157ff6b7aQ43020761-CEEE16AB-237E-498B-AEA6-8FAAEA1D4A60Q43260770-DF3EFD0C-F0C3-4726-8E43-E62E35DAF3D6Q45459975-9F82472A-9451-426E-8189-495D14907F1AQ47164162-B538601D-626D-47D6-9C02-6B376F94024AQ54527836-EB515C50-5EB7-41A1-8CD4-061FD12BA5CFQ55172681-629A6849-132A-45D9-94F7-D3ED98B092B9Q55176314-F34C5D39-30F1-43EE-AEE5-3EB7427C8791Q56167028-E32EECE7-77AC-4B95-B282-252F580AF146Q56281782-657A3EDF-5B79-4AFE-A397-E1707A15F40EQ56433177-76F887C8-FB0D-435E-9DD0-7EC0E3C531E1Q56459395-870B7D15-E005-4E6A-8152-DE8DF5D12537Q56480973-6123BE0C-C1C2-4383-A557-DF2D70BE562FQ56488421-0C4A27DC-4556-4E2E-9B5A-7A96315A8873Q56515785-55E97DF0-310B-4FC3-BBF4-960BE15B47BDQ56559390-F8E8C86C-A582-44F3-B527-A1005B36356DQ56810770-EA16C025-A87C-4F69-B4E2-A0D432D449DDQ57003732-58DA8CAB-2441-4A37-B51A-613447D773B4Q57069608-2BDEC4D5-3325-428D-93E3-B1AC393A8634Q57080820-2BEDE766-C6A5-4685-8785-5E92B24B9DD7Q57157274-22008D4D-8052-4BC0-932F-8363DA601420Q57319905-9CC4D81C-BF48-472F-86D1-304A2CC9CD7CQ57324043-30B8E8EF-50AF-4D0D-AA89-219C5149113BQ57416842-9720235B-FDC3-43E4-9F59-C7788A856FBD
P108
Q58407670-1EE50138-1899-459F-A65B-8CF50B680F45Q58849103-488C4D3B-461F-41B9-B27D-3FA5E49591ABQ58849164-0FE1726A-63CB-42C6-A34D-B85F8D3885A5Q61908774-CAB59BA0-9372-4770-ADAA-961C4BE1FA89Q61920814-E17CE195-1FF7-45EE-BC19-81BC0C78CA99Q61921090-D9C40A23-5170-4DEC-92E5-63A85700871EQ61921329-6484E87F-0D85-41D5-BF1B-60B100182757Q61921368-94F8747E-6503-4988-8EE8-726A974EA008Q61932780-DA2A6257-FEA4-49F3-8CE3-F47BD075E64FQ61934654-325F48BF-66A8-40D4-929A-9540677A6991Q61936012-D1666F5A-7C91-4731-9269-5C665AD3F350Q61936327-4F3F643E-BB79-4181-B19C-9D1C46B1571EQ61969533-9744DCC4-E2C1-41D7-81AB-0D635163AE4AQ61969815-F350DB11-1FE1-46DF-A26D-26E4A56BB2A1Q61975530-D630D0BE-427A-4EA8-B77E-99C7B5EE0B4DQ61978928-CD0CB988-7F75-44FE-8FA3-FF732611B0C2Q61979397-F4CDB852-44A9-4D41-A93F-0EE8410B539EQ62025685-51FBA1FD-4D07-4470-BE4D-2B09AFA7ACC7Q62110054-38188298-EEA4-4856-AB14-CCA933BED3CBQ62110345-97F58A6B-03AC-404B-807F-D5004971B32AQ62110505-8B79E43F-16B8-45FE-AD3F-964007BA5F77Q62110636-BA5FF72F-78DD-4DD9-A2F8-8EB917D34950Q62110664-CB9E1FF5-07FC-4FEE-A4E9-D13F545A2C91Q63012660-5CEA78E9-7E45-45C4-88F4-1967281E23D6Q63229104-F077B12A-8B48-43BC-AC1D-85FC675ADFBCQ63229695-5DE18555-5922-4FDF-8020-598A474F7B14Q63315542-9A86E7C2-F8BA-4609-9C55-4D9091C63681Q63316424-CB81DC00-D87C-484E-84D2-96482BE56388Q63317579-9FF8B0A8-E3AA-41CB-B5F9-683CB2F0E107Q63319514-1C9233E7-8DA3-4215-82EB-E36CF3C252F6Q63320432-D9DD0F67-65A7-4679-B5BD-4EC87C7A714AQ63322338-E4A2EF47-70FF-4BEF-B345-641924BD67EAQ63335861-E6A3DF79-7B1A-4F95-AF71-BF653CED0892Q63337033-C209C03E-31D9-47F5-A9A5-C3EA33193BBEQ63337967-D2466A09-586E-4159-9D8C-7B490EDE8B63Q63340296-CEAC424A-4EB6-49E1-92E4-AADDEAFE1820Q63340778-B7B15C48-E62A-4502-B42C-D2CEAB4074D7Q63403773-9156D48F-8DEB-4C9B-B051-4FA8F3CCAA9EQ63404887-77787927-0CDE-4A8F-85D6-B91639F230C3Q63571371-41BCE1A5-A9FD-4AFD-B9F6-FCA994E230E1
P6153

Beatson Institute for Cancer Research

Item
http://www.wikidata.org/entity/Q25188472
description
britische Organisation
@de
organisaatio
@fi
organisation
@en-gb
organization
@en
organizatë
@sq
name
Beatson Institute for Cancer Research
@cs
Beatson Institute for Cancer Research
@en
Beatson Institute for Cancer Research
@en-gb
type
label
Beatson Institute for Cancer Research
@cs
Beatson Institute for Cancer Research
@en
Beatson Institute for Cancer Research
@en-gb
altLabel
Cancer Research UK Beatson Institute
@en
Cancer Research UK Beatson Institute
@en-gb
The Beatson Institute for Cancer Research
@en
The Beatson Institute for Cancer Research
@en-gb
prefLabel
Beatson Institute for Cancer Research
@cs
Beatson Institute for Cancer Research
@en
Beatson Institute for Cancer Research
@en-gb
P17
P18
P213
P214
P244
P2671
P31
P3500
P571
P625
P7859
P214
P244
P2671
P17
P18
P213
P214
P244
P2671
P31
P3500
P571
P625
Point (-4.3228933333333 55.905855)
P7859